GBS GLUCOSE BIOSENSOR SYS

Intelligent Bio Solutions to Host Virtual Fireside Chat on Wednesday, December 11th at 4:30 p.m. ET

Intelligent Bio Solutions to Host Virtual Fireside Chat on Wednesday, December 11th at 4:30 p.m. ET

NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it will host a virtual fireside chat with Harry Simeonidis, President & CEO and Spiro Sakiris, CFO at 4:30 p.m. ET on December 11, 2024.

During the event, management will discuss the Company's recent clinical study results, path to FDA 510(k) submission, and offer investors an opportunity to ask questions.

Virtual Fireside Chat Details:

Dates: December 11, 2024

Presentation Time: 4:30 p.m. ET

Registration Link:

A Q&A portion will occur at the end of the call and a link to the recording of the presentation will be available on INBS’ after the event.

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.

For more information, visit: 

Company Contact:

Intelligent Bio Solutions Inc.

Investor & Media Contact: 

Valter Pinto, Managing Director 

KCSA Strategic Communications 

PH: (212) 896-1254 



EN
04/12/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on GLUCOSE BIOSENSOR SYS

 PRESS RELEASE

Intelligent Bio Solutions to Showcase Fingerprint Drug Testing at RISE...

Intelligent Bio Solutions to Showcase Fingerprint Drug Testing at RISE25 Conference from May 28-31, Supporting Innovation in U.S. Forensic Drug Testing INBS to participate with U.S. distribution partner SMARTOX at RISE25, the leading U.S. conference on addiction, mental health, and justice innovation which draws over 7,000 attendees annually With over 450 active accounts across 24 countries, INBS continues to meet growing global demand for reliable, on-site drug testing solutions across the workplace, treatment, and justice sectors NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Intelligent ...

 PRESS RELEASE

Intelligent Bio Solutions Showcases Rapid, Non-Invasive Drug Testing C...

Intelligent Bio Solutions Showcases Rapid, Non-Invasive Drug Testing Capabilities in Remote Queensland Workforce Deployment Completion of 160 tests conducted in less than 90 minutes demonstrates a level of speed and efficiency beyond the limits of traditional testing approaches NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of a high-volume workforce drug test for Barcaldine Regional Cou...

 PRESS RELEASE

Intelligent Bio Solutions Accelerates Global Adoption of Fingerprint D...

Intelligent Bio Solutions Accelerates Global Adoption of Fingerprint Drug Testing Company surpasses 450 accounts across 24 countries as global demand for fingerprint drug testing surges NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced recent growth highlights across its global operations, driven by new account acquisitions, expansion into new testing areas and sectors, and continued penetration into safety-critical...

 PRESS RELEASE

Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results a...

Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements 20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended March 31, 2025  35 new accounts and international growth during Q3 bring total active accounts to over 450 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent,...

 PRESS RELEASE

Intelligent Bio Solutions Drives Global Growth Through Multilingual Di...

Intelligent Bio Solutions Drives Global Growth Through Multilingual Digital Expansion Arabic, Italian, and Spanish-language websites unlock commercial access to regions representing over 1.4 billion people Multilingual rollout aligns with product readiness and accelerates international sales pipeline development NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the launch of three new localized websites in Arabi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch